NEW YORK & MIAMI — Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant… Read More
CDN $3-million donation to support diversity in dermatology research, training and care AbbVie, a global research and development-based biopharmaceutical company, has made a CDN $3-million donation to establish a pioneering AbbVie… Read More
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector Strengthened IP with patent filing for use of rare cannabinoids for the treatment… Read More
PROpel Is the First Phase 3 Trial to Show Clinical Benefit in Radiographic Progression-Free Survival With a PARP Inhibitor in This Setting KENILWORTH, N.J. — AstraZeneca and Merck (NYSE: MRK),… Read More
Vancouver, BC — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of… Read More
